Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.

He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, Wang H, Wu J, Shi X, Zhao S, Duan B, Zhu Y and 19 more

Show all authors

Zhou Y, Li F, Wang X, Ling H, Wang S, Li Q, Jiang F, Yang M, Bing S, Zheng Q, Ning J, Guo M, Bu Y, Guan L, Li Y, Yang L, Guo W, Pan H, Li X

The lancet. Diabetes & endocrinology22 Aug 2025Cited by 10 (Europe PMC)

PMID40854315DOI10.1016/s2213-8587(25)00196-2PepBankPUB-40854315

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, dulaglutide produced less HbA1c reduction than ecnoglutide 1·2 mg.
In plain wordsIn adults with diabetes on metformin, dulaglutide lowered long-term blood sugar less than ecnoglutide 1·2 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction versus ecnoglutide 1.2 mg
Study
n = 415
Comparator
Ecnoglutide 1·2 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg once weekly · subcutaneous · 32 weeksAs given in this study (human).
Measurements
Estimated treatment difference
−0.24%
Ecnoglutide 1.2 mg versus dulaglutide at week 32
Source sentences
Summary
Estimated treatment differences versus dulaglutide were -0·26% (95% CI -0·39 to -0·13; -2·84 mmol/mol [-4·29 to -1·38]) with ecnoglutide 0·6 mg and -0·24% (-0·38 to -0·11; -2·67 mmol/mol [-4·14 to -1·20]; p=0·0002 for superiority) with ecnoglutide 1·2 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included.
Summary · context
Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly.
Report a problemFND-4085431503
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, dulaglutide produced less HbA1c reduction than ecnoglutide 0·6 mg.
In plain wordsIn adults with diabetes on metformin, dulaglutide lowered long-term blood sugar less than ecnoglutide 0·6 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction versus ecnoglutide 0.6 mg
Study
n = 413
Comparator
Ecnoglutide 0·6 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg once weekly · subcutaneous · 32 weeksAs given in this study (human).
Measurements
Estimated treatment difference
−0.26%
Ecnoglutide 0.6 mg versus dulaglutide at week 32
Source sentences
Summary
Estimated treatment differences versus dulaglutide were -0·26% (95% CI -0·39 to -0·13; -2·84 mmol/mol [-4·29 to -1·38]) with ecnoglutide 0·6 mg and -0·24% (-0·38 to -0·11; -2·67 mmol/mol [-4·14 to -1·20]; p=0·0002 for superiority) with ecnoglutide 1·2 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included.
Summary · context
Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly.
Report a problemFND-4085431502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, dulaglutide reduced HbA1c by 1·65% at week 32.
In plain wordsIn adults with diabetes on metformin, dulaglutide lowered long-term blood sugar at week 32.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction at week 32
Study
n = 207
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg once weekly · subcutaneous · 32 weeksAs given in this study (human).
Measurements
Mean HbA1c reduction
1.65%
dulaglutide 1·5 mg, week 32, SE 0·05
Mean HbA1c change
−18.02 mmol/mol
dulaglutide 1·5 mg, week 32, SE 0·53
Source sentences
Summary
At week 32, mean HbA_1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg, 1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included.
Summary · context
Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly.
Report a problemFND-4085431501
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, HbA1c reductions with dulaglutide persisted to week 52.
In plain wordsIn adults with diabetes on metformin, lower long-term blood sugar with dulaglutide persisted to week 52.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSustained HbA1c reduction
Study
n = 207
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
HbA_1c reductions were sustained to week 52.
3 context sentences(design, population, supporting numbers)
Summary · context
At week 32, mean HbA_1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg, 1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide.
Summary · context
Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included.
Summary · context
Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly.
Report a problemFND-4085431504
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, six patients (3%) receiving dulaglutide discontinued treatment due to adverse events during 52 weeks.
In plain wordsIn adults with diabetes receiving dulaglutide, six patients (3%) stopped treatment because of adverse events during 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedDiscontinuation due to adverse events
Study
n = 207
Outcome group
Adverse events · Whole body
Studied dose
1·5 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Patients who discontinued due to adverse events
6 patients
dulaglutide 1·5 mg group, 52 weeks
Patients who discontinued due to adverse events
3%
dulaglutide 1·5 mg group, 52 weeks
Source sentences
Summary
During the 52 weeks, six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included.
Summary · context
Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly.
Report a problemFND-4085431505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT05680129

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Hangzhou Sciwind Biosciences Co., Ltd.n = 62310 Jan 2023 to 12 Oct 2024

T2DM · Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 8 May 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.